Newscast – Page 180 – media

Sanofi, Ablynx sign $2.7bn research, licensing pact

Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
- Source: pharmatimes
- 515
- July 21, 2017
Company Insight Market Views Sanofi Ablynx
NICE u-turn backs use of Teva’s asthma biologic

The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
- Source: pharmatimes
- 473
- July 21, 2017
asthma New Approvals NICE
EU nod for Gedeon’s novel antipsychotic Reagila

European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
- Source: pharmatimes
- 485
- July 20, 2017
New Approvals Reagila schizophrenia
ABPI seeks to challenge NICE reforms in court

The Association of the British Pharmaceutical Industry is seeking to challenge in court new rules on appraising medicines for NHS use, insisting that the changes will hinder patient access to the latest medical innovations.
- Source: pharmatimes
- 822
- July 20, 2017
innovation Policy
launch of a new online database

WHO and the Population Division of the United Nations Department of Economic and Social Affairs have launched a new, open-access database of laws, policies and health standards on abortion in countries worldwide. The database aims to promote greater transparency of abortion laws and policies, as well as to improve countries’ accountability for the protection of women and girls’ health and human rights.
- Source: WHO
- 414
- July 15, 2017
abortion Policy
Dune Medical’s MarginProbe destined for more than breast cancer, receives $12 million.

Dune Medical, which markets a tool that spots residual breast cancer cells following a lumpectomy, has raised $12.3 million. The funds will drive the development of the company’s technology for other types of cancer.
- Source: fiercebiotech
- 491
- July 10, 2017
breast cancer Market Views Researches
Sanofi snaps up Protein Sciences for $650 million

Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
- Source: pharmatimes
- 466
- July 7, 2017
Company Insight Market Views vaccine
Tumor-targeting MRI contrast developed, based on human protein

A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including early stage tumor detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.
- Source: drugdu
- 436
- July 7, 2017
breast cancer Clinical New Approvals tumor
Trillion in search of new partners

Trillium Therapeutics is seeking new partners as it looks over its pipeline with an eye to the future.
- Source: fiercebiotech
- 782
- July 5, 2017
EMA EU Market Views
MPs keen for close collaboration with EMA post Brexit

British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.
- Source: pharmatimes
- 874
- July 4, 2017
Company Insight EMA EU

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.